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Abstract 
Aims: The primary aim of the programme was a minimum of a 5% weight reduction of the initial weight, while 
the secondary outcomes were a reduction in participants’ body mass index (BMI), waist circumference (WC), blood 
pressure (BP), AUDIT-C score and an increase in the Mediterranean diet (MD) score and an improvement in physical 
activity levels.
Methods: This ’before and after’ study was a 10-week weight management (WM) programme and it was developed 
and delivered in community pharmacies in Patras chosen for convenience, thus consisting the first service of its type 
in Greece. The sample size was calculated (n = 96) based on the mean BMI for a Greek male and female individual, and 
the standard deviation (SD) of weight at baseline of 14 kg.
Results: Nearly every participant enrolled in the 20 participating pharmacies, 97.4% (n = 114/117), achieved the 
programme’s aim, losing at least 5% of their initial weight. The mean percentage of total weight loss of the 117 partici-
pants at the 10th week was 8.97% (SD 2.65), and the t-test showed statistically significant results (P-value < 0.001; 95% 
CI [8.48, 9.45]). A significant reduction in the waist-to-height ratio (WHtR) was observed in both male (P-value = 0.004) 
and female (P-value < 0.001) participants. The participants’ BP and AUDIT-C score and physical activity levels signifi-
cantly improved (P-value < 0.001), as well as their MD score.
Conclusion: This study provides the first evidence that Greek pharmacists have the potential to play an important 
role within primary healthcare and that after training they are able to provide public health services for both the pub-
lic’s benefit and their clinical role enhancement.
Keywords: Pharmacy-led weight management programme, Greek pharmacists’ new clinical role, CVD prevention, 
Preventive cardiology, Community pharmacy, Public health
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Introduction
Weight reduction leads to physical, psychological and 
social health benefits. According to Vidal et al. [1], 5–10% 
weight loss brings about beneficial improvements in fast-
ing glycaemia, glycated haemoglobin (HbA1c), both dias-
tolic and systolic blood pressure (BP) and plasma lipid 
profile. In addition, weight loss can reduce the need to 
use of glucose lowering medications and minimise the 
risk of co-morbidities related to type II diabetes [1]. In 
fact, moderate weight reduction can decrease the total 
mortality of type II diabetic patients by 25% [1]. Mac-
Mahon et al. [2], identified that each Kg lost can achieve 
an average reduction in systolic and diastolic BP of 0.68 
and 0.34  mmHg, respectively (around 1  mmHg over-
all). Dattilo et  al. [3] stated that losing 1  kg can reduce 
serum cholesterol by 2.28  mg/dl (0.059  mmol/L), low 
density lipoprotein (LDL) cholesterol by 0.91  mg/
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dl (0.023  mmol/L), and triglycerides by 1.54  mg/dl 
(0.017 mmol/L).
Dietary pattern has been shown to influence adiposity 
and to increase the risk of developing obesity [4]. Meas-
ures of obesity include body weight, waist circumference 
(WC) and body mass index (BMI). However, it is broadly 
recognised that WC is a better indicator than BMI or 
weight in terms of identifying the risk of cardiovascular 
disease (CVD) and/or diabetes [5, 6]. WC is a detector of 
abdominal obesity. The waist-to-height ratio (WHtR) is 
also a proxy of visceral (central) obesity [7, 8], which has 
been newly identified as an “early health risk” detector. 
According to Ashwell et al. [9], WHtR of < 0.5 is associ-
ated with no increased risk; a reading of ≥ 0.5 and < 0.6 is 
associated with increased risk, while WHtR ≥ 0.6 is asso-
ciated with a very high risk of adipose obesity.
A cardio-protective diet can help individuals to mini-
mise their risk of developing CVD. A cardio-protective 
diet mainly includes the consumption of less than 5  g 
of salt daily, 200 g or more of fruits and vegetables (2–3 
portions each), fish (twice a week, one portion of which 
should be an oily fish such as salmon, sardine, etc.), 30 g 
(a handful) of unsalted nuts daily and 30–45  g of fibre 
daily, preferably from wholegrain products [10]. The 
cardio-protective diet is in line with the Mediterranean 
diet (MD) [11] consisting primarily of fruit, vegetables, 
legumes, whole grains, fish and olive oil, with moderate 
amounts of red meat and alcohol [4, 12].
It has been established that adherence to a MD reduces 
the risk of developing CVD [13–16]. Sofi et  al. [17] 
stated that MD is a model of healthy eating because of its 
positive outcomes on an individual’s health. A MD also 
has a regulating effect on CVD risk factors and condi-
tions including BP, cholesterol levels, insulin resistance, 
endothelial function and inflammation, although all these 
effects are linked to an apparent synergy of the entire 
dietary pattern, rather than being the result of any of 
its components individually [18, 19]. Therefore, the MD 
should be considered as a factor with respect to preven-
tion of disease [20].
EMENO project statistics [21] have shown that Greece 
is in dire need of weight reduction, especially in Patras. 
There is not only a need to minimise the risks of devel-
oping obesity-related medical conditions and CVD, but 
also to educate the general public to achieve better health 
outcomes.
Pharmacists are primary healthcare professionals 
(HCPs) and they have an important role in increasing the 
public’s awareness about obesity and its consequences. 
Additionally, based on a resent published report stated 
that pharmacists in the community have clinical roles 
over the last 50  years [22]. According to Peletidi et  al. 
[23], Greek pharmacists were found to be eager to 
expand their role and offer public health services, regard-
ing weight control in particular. There is clear evidence 
that UK pharmacists and pharmacy staff achieved posi-
tive results upon offering CVD prevention public health 
services including locally commissioned weight man-
agement (WM) services to the general public [24]. 
The WM service offered in the UK could therefore act 
as a reference for delivering such a service in Greece 
through pharmacies. The study aimed to design, initiate 
and evaluate a WM programme offered by pharmacists 
to the population of Patras in Greece. The primary out-
come of the programme was for participants to achieve 
a minimum of 5% reduction from their initial weight. 
Secondary outcomes included reduction of BMI, WC, 
BP, Alcohol Screening Tool (AUDIT)-C score, increase in 
physical activity and increase in the MD score.
Methods
This primary care research-based study [25] used 
mixed research methods [26]. Based on the Toshakkari 
and Creswell study [27] mixed research methods are 
described as “research in which the investigator collects 
and analyses data, integrates the findings and draws infer-
ences, using both qualitative and quantitative approaches 
and methods in a single study or programme of inquiry”. 
Mixed research methods can theoretically address a 
variety of research questions contained in a single study, 
aimed at exploring the same research issue, but necessi-
tate a number of different research approaches.
Study design and setting
This ‘before and after’ study designed based on the evi-
dence identified in the UK WM locally commissioned 
service [24]. Several materials were designed for the 
purpose of this study. These included three booklets 
(Initial Screening booklet, Results booklet and Person-
alised Advice booklet) and the programme’s poster. The 
Personalised Advice booklet outline was inspired by the 
“Weigh2Go” service’s manual, a WM service which is 
currently being offered in Kingston and Richmond LPC 
in the UK [28].
According to the Pharmaceutical Association of 
Achaea, there are 223 pharmacies within the municipality 
of Patras. Pharmacies located in Patras were approached 
between March and May 2016 and were invited to par-
ticipate in the pharmacy-led WM programme (via 
e-mail, telephone, personal contact). Thirty pharmacists 
expressed an interest in participating in the programme 
with 26 pharmacists finally actually taking part in the 
programme.
The required minimum sample size to show statistical 
significance was 96 participants. The minimum sample 
size was calculated based on a 5% weight loss pre- and 
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post-intervention using the paired t-test sample size cal-
culation (using a significance level of 0.05 for two sided 
tests) for before–after study, in accordance with previ-
ous studies [29, 30]. The sample size calculation used 
was based on the standard deviation of weight at base-
line (initial screening) which was 14 kg (14 kg is the dif-
ference between two BMI classifications, e.g. overweight 
and obese I) and on the difference in mean weight of 
4  kg, based on a 5% weight reduction. This calculation 
used online calculators based on Rosner et  al. [31, 32]. 
To consider drop-outs, if participants dropped out half-
way through the programme (5  weeks), they could be 
replaced.
All relevant documentations were ethically approved 
by the Pharmaceutical Association of Achaia (Ref: 56), 
the Sub-Mayoralty for Health Social Policy and Welfare 
of the Municipality of Patras (Ref: 115/32617) (March 
2016) as well as by the Science Engineering and Comput-
ing (SEC) Ethics Committee (ID: 1516/030) in Kingston 
University (KU) London (May 2016). All materials were 
validated with a Greek pharmacist (member of the Phar-
maceutical Association of Achaia) with no major changes 
recommended. Participants information sheets (PIS) 
including all the necessary information were provided 
before programme’s delivery to both providers (phar-
macists) and receivers (participants). Additionally, they 
contained a consent form to be completed by the phar-
macists and the participants, respectively.
The programme was advertised through posters placed 
on display in participating pharmacies or by the pharma-
cists themselves.
Intervention
The programme comprised 11 (including the initial 
screening) consecutive visits. Enrolment on the pro-
gramme was made upon completion of initial screening 
to ensure participants met the eligibility criteria (adult 
men and women (≥ 18 years old) without any diagnosed 
risk conditions such as diabetes, hypertension and dys-
lipidaemia, or any CVD, or cancer or any other chronic 
conditions, BMI ≥ 25 and ≤ 35  kg/m2 unless a cardiolo-
gist confirmed their eligibility to participate, those with-
out specific dietary habits, such as vegetarians, vegans, 
or those who have special dietary requirements such as a 
gluten-free regime and those with no food allergies and/
or food intolerance, anyone who could freely give consent 
without language barriers, mental capacity, or learning 
disability. Candidates who met the inclusion criteria were 
then enrolled in the 10-week programme.
Initial screening included a series of assessments to 
enable pharmacists to identify if the participant was eli-
gible for the programme. Initially, demographic infor-
mation (age, gender, educational status and monthly 
income) was taken. Medical lifestyle assessments (indi-
vidual’s smoking status, alcohol status and eating sta-
tus (their typical diet, the number of meals/snacks they 
consume) were also taken. An important aspect of this 
WM programme was that it was the first study assess-
ing other important weight gain contributors including 
alcohol intake (by using a shorter version of the AUDIT 
score (AUDIT-C)), and adherence to the MD (based on 
participants’ answers to 14 questions) [11]. Based on Tra-
versy et al. [33], 1 g of alcohol gives 7.1 kcal (29 kJ) and in 
conjunction with the energy acquired from other dietary 
sources can promote weight gain. The MD score was an 
essential addition to the programme as an improvement 
of 2 points in a MD score was found to be associated 
with a decrease of 9% in overall mortality, 9% in CVD-
related mortality [17] and it can help in weight reduction 
[34]. The programme also included a BP measurement. 
Although there are previous studies assessing BP within a 
pharmacy-led weight management service [35–37], most 
of them did not report their findings [35, 36].
Eligible participants who entered the programme were 
assigned a “Results” booklet and received a “Personalised 
Advice” booklet and a “Meal Planner”. As part of the pro-
gramme participants were asked to maintain food and 
exercise diaries weekly, as well as to record their weekly 
weight measurements. A diary was provided in the book-
let for participants to fill out.
On each visit, pharmacists measured participants’ 
weight, WC, BP and HR, and also assessed participants 
reported physical activity levels. In addition, they calcu-
lated their BMI, and determined whether participants 
had reduced or increased their body weight, their BMI 
or WC. Through this, pharmacists were able to identify 
whether the programme had affected participants posi-
tively or negatively.
The frequency of the visits (biweekly) and the duration 
of the service were planned based on the experience of 
UK pharmacists and pharmacy staff who offer weight 
management service in the UK [24]. Details of the visits 
are described below (Table 1).
Data collection
The data recorded by pharmacists were collected at the 
end of the programme in January 2017 in person. Addi-
tionally, the researcher collected participants’ weight 
either self-reported or measured by the pharmacists in 
October 2017 (9–12  months after the programme’s ter-
mination depending on each participant starting date). 
The programme adhered to the Common Law Duty of 
Confidentiality via the Data Protection Act 1998.[38, 
39] Pharmacists kept all participants’ details and data, 
including consent forms, in a separate folder for each 
participant, maintained in a securely locked drawer or 
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cabinet until the programme’s end. All Excel spread-
sheets were kept in encrypted and password-protected 
files on a computer, so that only they would have access 
to them. After the termination of the programme, all 
collected data including participants’ measurements as 
well as participants’ and service providers’ consent forms 
were provided to the researcher by the pharmacists. For 
pharmacies that used the Excel spreadsheets to record 
results, the completed Excel spreadsheets were saved to 
the researcher’s USB flash drive to ensure confidentiality 
of the transferred data. All the anonymised data was col-
lected either in hard copies (booklets) or in Excel were 
stored in a secure place in a locked cabinet/password 
protected file at KU. Participants were coded to maintain 
anonymity based on the number of the pharmacy which 
provided them with the programme, and in numeri-
cal order. For example: Weight Management (WM): 
WM1_1, WM3_12, etc.
Data analysis
All data collected from each of the participating phar-
macies were entered into a Microsoft Excel 2010 spread-
sheet and then, they were exported into IBM Statistical 
Package for Social Sciences (SPSS) Version 23 for statisti-
cal analysis. The results are expressed as mean differences 
with 95% confidence intervals (CIs) and P-values. CIs not 
including zero and P-values less than 0.05 were consid-
ered as statistically significant.
The programme was considered successful if a par-
ticipant achieved at least a 5% reduction in their initial 
weight, which was the stated goal of the programme. 
To test if the participants’ total percentage weight loss 
was ≥ 5%, the one-sample t-test was used. Addition-
ally, to examine participants’ weight change between the 
last visit and the follow-up period (after 9–12 months of 
the programme’s termination), a one-sample t-test was 
conducted. Furthermore, to test the effect of the pro-
gramme on participants’ BMI, a paired-samples t-test 
was used comparing participants’ BMI at the first visit 
(initial screening) and the last visit (programme comple-
tion). In addition, an unpaired samples t-test was con-
ducted to assess the impact of gender on BMI reduction.
According to NICE guidelines [40], the classification of 
WC as low, high, or very high is different between males 
and females. Therefore, the effect of the programme on 
participants’ WC was tested separately for male and 
female participants using the paired-samples t-test. 
Moreover, the effect of gender (female/male) on WC 
reduction was tested using the unpaired samples t-test. 
The WHtR, as mentioned previously, is a proxy of vis-
ceral (central) obesity [7, 8], which has been newly iden-
tified as an “early health risk” detector. To examine the 
programme’s effect on reducing participants WHtR the 
McNemar’s test was utilised (per gender). Furthermore, 
in order to examine the effect of programme participa-
tion on improving BP status (BP readings were stratified 
into three groups: 1 = optimal + normal, 2 = high normal, 
3 = hypertensive) the Sign test was conducted.
Additionally, to test the effect of the programme on 
participants’ exercise habits, a paired-samples t-test was 
conducted comparing participants’ exercise reported at 
the first visit (initial screening) and the last visit (pro-
gramme completion). In order to examine if the changes 
(increase/decrease) of mean exercise time per visit dur-
ing the programme (i.e. the participant spent the same/
less time or more time for exercise than the previous 
visit) affected the changes (increase/decrease) in weight 
loss (i.e. the participant had the same/less weight loss or 
more weight loss than the previous visit) a Chi-square 
test was conducted.
As stated above, an increase in the MD score of 2 
points is related to a 9% decrease in CVD incidence and 
Table 1 Details of the visits included in the weight management programme
BMI body mass index, BP blood pressure, CVD cardiovascular disease, WC waist circumference, HR heart rate
Visit 1 (initial screening) Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Week 1 Week 3 Week 5 Week 7 Week 9 Week 11
If eligible for the programme:
- distribution of the “personalised 
advice” and results booklets
- goal setting
- European Society of Cardiology (esc) 
healthy diet characteristics and 
exercise recommendations (2016 
esc guidelines on CVD prevention in 
clinical practice) [10]
Importance of healthy-










How to maintain the 
weight loss
- discussion of achieve-
ments
- completion of service’s 
evaluation question-
naires
- further follow-up if 
requested
Monitor parameters
Monitoring period (visit 2–5): weight, WC, BMI, BP, HR, weight loss/gain between visits, physical activity levels
Final visit (visit 6): weight, WC, BMI, BP, HR, final audit-c score, % total weight loss, % total wc loss, % total bmi alteration
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mortality [11, 4]. Therefore, in order to examine if par-
ticipation in the WM programme had at least a 2-point 
increase in the MD score, a one-sample t-test was con-
ducted. Finally, the programme’s effect on participants’ 
alcohol consumption habits was also assessed. The 
AUDIT-C score was calculated by the pharmacists at 
both the initial screening and the last visit. To test the 




Of the 26 pharmacists who agreed to participate and 
deliver the WM programme, only 21 pharmacists were 
able to enrol participants. The demographics of the 21 
pharmacists who recruited participants are described in 
Table 2 below.
Analysis of participants’ measurement data
A total of 119 individuals, living in Patras, expressed 
an interest in enrolling onto the programme. However, 
only 117 participants completed the informed consent 
form to take part in the study. All enrolled participants 
completed the 6 biweekly visits (including the initial 
screening). None of the participants requested a further 
follow-up, which was an option after completion of the 
core 10-week monitoring period. The demographics of 
the sample taken at the initial screening are described in 
Table 3.
A comparison between the baseline data collected at 
the initial screening (1st visit) and that collected at the 
end of the programme (last visit 6th visit) was conducted 
to identify the effect of the pharmacy-led weight manage-
ment programme on participants’ total weight, BMI and 
WC. The results are summarised in Table 4. In addition, a 
comparison was also made after 9–12 months’ follow-up 
in participants’ weight results.
The mean weight was reduced from 86.98  kg 
(SD = 16.47) at the initial screening to 79.24  kg 
(SD = 15.94) at the sixth (last) visit. The mean total weight 
loss was 7.73 kg (SD = 2.51) at the last visit. The primary 
outcome for the programme was for participants to 
achieve at least a 5% weight reduction on completing the 
programme. Nearly every participant (97.4%, (n = 114) 
achieved the programme’s aim. More specifically, 50.4% 
(n = 59) lost between 5 and 10% of their initial weight 
and 47% (n = 55) lost ≥ 10% of their initial weight while 
3 participants (2.6%) did not achieve the aim of the pro-
gramme (Table  4). The mean percentage total weight 
loss of the 117 participants at the 10th week was 8.97% 
(SD 2.65) (minimum % total weight loss 0 and maximum 
% total weight loss 16) (Table  4), and the t-test showed 
statistically significant results (P-value < 0.001; 95% 
CI [8.48, 9.45]), proving that the programme was suc-
cessful. Furthermore, participants were asked to either 
self-report or to visit the pharmacies in which they had 
participated in the weight management programme, to 
measure their weight at 9–12 months follow-up. Of 117 
individuals who participated into the programme, 111 
(94.9%) either self-reported or had their weight measured 
by their pharmacist to identify if they were maintaining 
their weight loss. The analysis indicated that almost an 
equal number of participants either lost (n = 49) or main-
tained their weight (n = 48) compared with the measured 
weight at the last visit. Only a minority (n = 14) gained 
weight (Table 5). More specifically, of those who lost fur-
ther weight, 18.8% (n = 22) of participants lost ≤ 1 kg and 
23.1% (n = 27) between 1 and 5  kg (Table  5). Addition-
ally, of those participants who gained weight, 5.1% (n = 6) 
gained ≤ 1 kg, 6% (n = 7) gained between 1 and 5 kg and 
only 0.9% (n = 1) gained > 5 kg. In terms of the total per-
centage of weight loss in the follow-up, more than half of 
the sample (45.3%, n = 53) still achieved more than 10% 
weight loss and 42.7% (n = 50) achieved between 5 and 
10% total weight loss. Only 6.8% had a total percentage 
weight loss of below 5% (Table 5).
BMI achievements
Regarding participants’ BMI, it was observed that the 
mean BMI was continuously reduced during visits from 
31.14  kg/m2 at the first visit (SD = 4.34) to 28.36  kg/m2 
Table 2 Personal and practice demographic information of 
pharmacists who recruited individuals (n = 21)
The mean total time a pharmacist spent for all six sessions was 151.43 min 
(SD = 25.84) (approximately 2 h and 30 min) with a range from 97.5 to 
198.75 min
Gender distribution
Sex Frequency (n) Percentage (%)
 Males 12 57.1
 Females 9 42.9
Age distribution
Age range Frequency (n) Percentage (%)
 25–34 years 6 28.6
 35–44 years 10 47.6
 45–54 years 3 14.3
 55–69 years 2 9.5
Years of experience
Year range Frequency (n) Percentage (%)
  ≤ 5 years 6 28.6
 6–10 years 5 23.8
 11–15 years 4 19
 16–20 years 2 9.5
  ≥ 20 years 4 19
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Table 3 Characteristics of the participants at initial visit (n = 117)
Gender distribution Sex Frequency (n) Percentage (%)
Males 32 27.4
Females 85 72.6
Age distribution Age range Frequency (n) Percentage (%)
18–24 years 6 5.1
25–34 years 18 15.4
35–44 years 29 24.8
45–54 years 32 27.4
 > 55 years 32 27.4
Educational level Type Frequency (n) Percentage (%)
Primary school 3 2.6
Secondary school 49 41.9
Higher education (college/university) 65 55.6
Monthly income Euros (€) Frequency (n) Percentage (%)
 < 500 26 22.2
500–999 53 45.3
1000–1500 22 18.8
 > 1500 7 6.0
No reported income 9 7.7
Smoking status
*Pack years can be 
calculated as fol-
lows: number of 
pack-years = num-
ber of cigarettes 
smoked per 
day/20) × number 
of years smoked
Smokers Frequency (n) Percentage (%)
No 84 71.8
Yes 33 28.2
Pack years* Frequency 
(n = 33)
Percentage (%)
 ≤ 15 13 39.4
 > 15 20 60.6
Have you ever thought to stop smoking? (n = 33)
Answer Frequency Percentage (%)
Yes 28 84.8
No 5 15.2
Do you have concerns that when you quit smoking you will gain weight? (n = 33)
Answer Frequency Percentage (%)
Yes 25 75.8
No 8 24.2
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at the sixth visit (SD = 4.18) (Table 4) as BMI is related to 
weight reduction.
In terms of the participants’ BMI achievements, at the 
end of the 10-week programme (last visit), 27 (23.1%) of 
the participants achieved a normal BMI, n = 56 (47.9%) 
were overweight, 25 (21.4%) were obese class I, 7 (6%) 
obese class II, and 2 (1.7%) obese class III.
Participants (27 out of 56) who were enrolled in the 
programme as “overweight (25–29.9  kg/m2)” achieved a 
“normal (18.5–24.9 kg/m2)” BMI at its end. Additionally, 
27 out of the 41 participants who were initially classified 
as “obese class I (30–34.9 kg/m2)” shifted to “overweight 
(25–29.9 kg/m2)”, 11 out of 14 participants who initially 
classified as “obese class II (35–39.9  kg/m2)” remained 
obese but shifted to “obese class I (30–34.9  kg/m2)”, 
and 4 out of 6 who initially classified as “obese class III 
(≥ 40 kg/m2)” reached “obese class II (35–39.9 kg/m2)”.
A paired-samples t-test was conducted to evaluate the 
impact of the programme on participants’ BMI. There 
was a statistically significant decrease in BMI between 
the initial visit (mean = 31.14, SD = 4.34) and the last 
visit/end of the programme (mean = 28.36, SD = 4.18); 
t (116) = 36.01, P-value < 0.001). Additionally, there was 
no statistically significant difference between males 
(mean = 2.63, with SD = 0.93) and females (mean = 2.83 
with SD = 0.79), P-value = 0.234.
After 9–12  months follow-up it was observed that of 
the 111 participants who either self-reported or visited 
the pharmacist to measure their weight, 104 participants 
remained in the same BMI category and 4 participants 
Table 3 (continued)
Eating status Typical diet Frequency (n) Percentage (%)
Mainly vegetables 2 1.7
Mainly meat (including poultry and fish) 12 10.3
Mainly meat (including poultry and fish) and vegetables 12 10.3
Variety of foods (e.g. fruits, vegetables, meat, dairy sweets, fatty and 
starchy foods)
91 77.8
Reported meals/day Reported snacks/day
Number of meals Frequency (n) Percentage (%) Number 
of 
snacks
Frequency (n) Percentage (%)
1 8 6.8 0 39 33.3
2 56 47.9 1 28 23.9
3 38 32.5 2 29 24.8
4 11 9.4 3 11 9.4
5 4 3.4 4 9 7.7
 > 4 1 0.9
Mediterranean diet score Frequency (n) Percentage (%)




 ≥ 10 10 8.5
Physical activity (PA) No reported PA (participants) PA < 150 min (participants) PA ≥ 150 min (participants)
Frequency (n) 28 38 51
Percentage (%) 23.9 32.5 43.6
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improved their BMI classification (2 participants from 
overweight moved to normal weight, 1 from obese class 
I to overweight and 1 from obese class II to obese class 
I). Interestingly, 3 participants moved from a better BMI 
category to a worse one. More specifically, 1 participant 
moved from normal BMI to overweight, 1 participant 
from overweight to obese class I and 1 participant from 
obese class I to obese class II.
Table 5 Self-reported or measured weight at 9 to 12 months after termination of the programme (n = 111)
Furthermore, a one-sample t-test showed that the mean percentage of weight change between the last and the follow-up visit (mean = -0.57, SD = 1.79) was 
statistically significant (P-value < 0.001)
Weight self-reported/measured (kg) after 9–12 months















Changes in weight (comparison between last visit and follow-up 
period)
Frequency (n) Percentage (%)
Weight loss (n = 49)
Weight loss ≤ 1 kg 22 18.8
Weight loss 1– ≤ 5 kg 27 23.1
Weight gain (n = 14)
Weight gain ≤ 1 kg 6 5.1
Weight gain 1– ≤ 5 kg 7 6.0
Weight gain > 5 kg 1 0.9
No change between the weight measured at the last visit (n = 48)
No change 48 41.0
% total weight loss after 9–12 months follow-up (compared to initial 
visit)
Frequency (n) Percentage (%)
 0–5% 8 6.8
 5–10% 50 42.7
  > 10% 53 45.3
Males (n = 32)
 0–5% 3 9.4
 5–10% 16 50.0
  > 10% 13 40.6
Females (n = 79)
 0–5% 5 5.9
 5–10% 34 40.0
  > 10% 40 47.1
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Waist circumference achievements
In terms of gender, the WC decreased from 116.59  cm, 
(SD = 13.40) at the first visit to 108.58  cm (SD = 12.69) 
at the sixth visit for male participants. For females, the 
decrease was from 102.68  cm (SD = 13.81) at the first 
visit, to 94.95  cm (SD = 12.42), at the sixth visit. At the 
end of the programme, a number of male participants 
(7/32) not only reduced their WC but improved their 
WC classification. Six male participants shifted from a 
classification of very high to high, and 1 participant from 
high to low. The mean value of the total WC reduction 
for males was 8.02 cm (SD = 3.01) (95% CI [6.93, 9.10]). 
The programme’s impact on males’ WC was tested 
using a paired-samples t-test. It was identified that there 
was a statistically significant decrease in WC between 
the first (mean = 116.59, SD = 13.40) and last visit 
(mean = 108.58, SD = 12.69), P-value < 0.001.
In addition, almost 1 in 4 women (21/85) positively 
changed their WC classification. More specifically, 7 
women participants shifted from high risk to low risk and 
14 from very high risk to high risk. The mean value of the 
total WC reduction in females was 7.73 cm (SD = 4.14), 
(95% CI [6.84, 8.62]). A paired-samples t-test showed a 
statistically significant decrease in females’ WC between 
the first (mean = 102.68, SD = 13.82) and last visit 
(mean = 94.95, SD = 12.42), P-value < 0.001.
Finally, an independent samples t-test was used to 
test the effect of gender on the WC reduction show-
ing no statistically significant difference between males 
(mean = 8.02, SD = 3.01) and females (mean = 7.73, 
SD = 4.14), P-value = 0.723.
Correlation between BMI and WC in identifying 
CVD risk
According to NICE guidelines [40], the correlation of 
BMI to WC can indicate health risks related to being 
overweight or obese. According to the male participants’ 
results, 19 were found at the initial screening to be “very 
high risk”, 10 “high risk”, 2 “increased risk” and only 1 
participant with “no increased risk”. The pharmacy-led 
weight management programme was not only success-
ful in reducing weight, BMI and WC, but also helped 
to decrease the health risks associated with being over-
weight and obese. After the programme, a decrease in 
the number of male participants with a “very high risk” 
was observed, from 19 to 11 individuals. Additionally, 
an increase in male participants with “no increased risk” 
(from 1 to 5 males), with “increased risk” (from 2 to 4) 
and in participants with “high risk” (from 10 to 12) was 
observed (Table 6).
In terms of female participants before the programme 
delivery, 2 females were found to have “no increased 
risk”, whereas after the programme delivery this number 
increased by 24 participants (total 26 females). Addition-
ally, 9 females were identified as having an “increased 
risk” before the service, whereas after the service 10 
females were found to be at “increased risk”. The next 
important change was that of 34 females who were found 
Table 6 Correlation between the BMI, WC and the CVD risk at the Initial and last visit for male participants
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to be at “high risk” after the service delivery, the number 
of participants in this category was reduced to 27. Finally, 
before the programme delivery there were 40 females at 
“very high risk”, but after the programme, the number 
of female participants in this category was reduced to 
almost half (n = 22) (Table 7).
WHtR and abdominal obesity
After the programme’s termination almost a quarter of 
participants (25%, n = 8 males and 22.3%, n = 19 females) 
moved from a WHtR ≥ 0.6 to a WHtR < 0.6.
In order to examine the effect of the programme on 
reducing the WHtR, of males from (WHtR ≥ 0.6 to 
WHtR < 0.6) the McNemar’s test was conducted. The 
effect of the programme was statistically significant 
(P-value = 0.004). Similarly, the reduction of WHtR for 
female participants from WHtR ≥ 0.6 to WHtR < 0.6 was 
statistically significant (P-value < 0.001).
Physical activity achievements
The majority of participants (54.7%) were reported to 
exercise more than 150  min per week during the pro-
gramme (mean = 230.94, SD = 83.06) compared to 43.6% 
(mean = 248.53, SD = 82.7) at start of the programme. 
Even if participants showed an increase in their physi-
cal activity from initial screening to the last week, the 
results did not indicate any statistically significant dif-
ference between the mean percentage of total weight 
loss between group 1 (participants who exercised less 
than the recommended 150  min weekly) (mean = 8.91, 
SD = 3.05) and group 2 (participants who exercised 
equal or more than the recommended 150  min weekly) 
(mean = 9.02, SD = 2.29), P-value = 0.829.
BP achievements
In order to examine if participants’ BP status was 
improved through the programme, three groups were 
generated: optimal and normal BP, high normal BP, and 
hypertensive. Sixteen participants out of 19 who were 
initially identified with hypertension moved to optimal- 
normal or high normal levels, with only 3 remaining in 
the hypertensive category after the programme’s termi-
nation. The Sign test was conducted showing statistically 
significant results (P-value < 0.001) between the initial BP 
classification and the last visit.
Effect of the programme on the AUDIT‑C score
The weight management programme also contributed to 
the AUDIT-C score reduction of the participants. After 
the WM programme, none of the participants identified 
with an AUDIT-C score between 8 and 10, compared 
with the initial screening scores. More specifically, 83.8% 
Table 7 Correlation between the BMI, WC and the CVD risk at the Initial and last visit for female participants
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(n = 67/80) of the participants decreased their AUDIT-C 
score after the programme’s conclusion. The reduction 
is participants’ alcohol consumption as measured by the 
AUDIT-C score was found to be statistically significant 
(mean AUDIT-C at end of programme = 1.86, SD = 1.59, 
mean AUDIT-C at start of programme = 3.63, SD = 2.29, 
P-value < 0.001).
Mediterranean diet and WM programme
The MD score was also calculated for each participant 
at the initial and the last visit. It is obvious that after the 
programme’s delivery there was an increase in the mean 
MD score. Additionally, there was an increase in par-
ticipants whom their score was greater than or equal to 
10 (n = 10, 8.5% at initial screening and n = 33, 28.2% 
at the last visit). The high score indicates that better 
adherence to the MD was achieved. A paired-samples 
t-test showed that the mean MD score taken at the last 
visit (mean = 8.33, SD = 1.99) is statistically significantly 
greater than the mean MD score at the initial screening; t 
(116) = -13.99, P-value < 0.001.
As mentioned previously, an increase of 2 points in 
the MD score is related to a 9% decrease in CVD risk 
[4, 11]. Interestingly, after the end of the programme, 
44 participants (37.6%) increased their Mediterranean 
score by 1 point and 48 participants (41%) increased 
it by at least two. However, the one-sample t-test 
showed that the mean increase in Mediterranean score 
(mean = 1.49, SD = 1.15) was not statistically significant; 
t (116) = -4.826, P-value = 1.
Discussion
This pharmacy-led WM programme was the first attempt 
by Greek pharmacists to expand their role by delivering 
public health services. The programme was chosen in 
accordance with the preferences of the Greek pharma-
cists [23]. It was delivered in Patras, owing to its conveni-
ent location and the local knowledge of the researcher 
and was supported by the obesity statistics in that city.
Direct comparisons with other pharmacy-led weight 
management service studies (i.e. studies which were con-
ducted in the UK) cannot be made as the demographics, 
structure of the service (i.e. duration of the programme, 
number of visits, inclusion criteria) and the situation 
in each country are not the same. For example, in this 
study, all participants were White origin. However, in 
the majority of worldwide studies, the participants were 
from various ethnic groups such as Black and Asians. In 
addition, all information provided to participants in this 
study, including recipes and the food options that they 
had to choose from, were based on the Mediterranean 
culture and traditions. Furthermore, all the guidelines 
they were given, including alcohol consumption, were 
based on the ESC European guidelines for CVD preven-
tion in clinical practice [10]. An important difference 
between this WM programme and the UK WM services 
offered is the use of a structured approach, something 
that is already implemented by the UK service providers 
[41]. All pharmacists received the same training, and had 
a structured way of delivering the programme, including 
the way in which they collected the results, the visits, as 
well as the advice given to the participants, which incor-
porated both verbal and written communication as both 
were deemed important by interviewed pharmacists in 
a previous study [23]. Thus, regardless of where partici-
pants received the programme, they had the same book-
lets containing the appropriate information about weight 
loss and improving their lifestyle.
With regards to the characteristics of the sample popu-
lation that received the intervention, the majority of the 
participants were females, a finding that was observed 
in similar studies [42, 43]. This may be explained by the 
Poobalan et  al. [44] study, which indicated that men do 
not seek early medical advice compared to women, lead-
ing to poorer health outcomes for men. Furthermore, the 
mean BMI of the female sample population was 30.78 kg/
m2 and for males was 32.10  kg/m2, classifying them as 
obese class I. This finding is not in line with the national 
mean BMI for males and females (28  kg/m2 and 27  kg/
m2, respectively), which classify them as overweight.
An interesting finding was that there were more female 
smokers than males in the sample. According to the 
WHO, the increase of tobacco smoking in the female 
adult population can be attributed not just to social fac-
tors and females’ increasing economic resources, but 
also to the tobacco industry’s marketing of cigarettes 
to women as a symbol of emancipation [45]. Interest-
ingly, the majority of participants who were smokers 
(75.8% (n = 25/33)) did not want to quit smoking, as they 
believed that they would gain weight. This agrees with 
various studies that state that most smokers gain weight 
when quitting smoking, which can interfere with cessa-
tion efforts [46]. Although cessation-related weight gain 
is modest [46], many smokers report gaining more than 
10 kg, placing them at high risk of obesity-related chronic 
diseases.
At the end, the programme achieved a mean weight loss 
of 7.73 kg (SD = 2.51) for both genders. Although, direct 
comparisons cannot be made with other weight manage-
ment programmes; it is however worth pointing out that 
in a similar programme (12-week programme) conducted 
in the UK, the mean weight loss achieved was 2.1 kg in 
the pharmacy arm (total number of participants = 183) 
[42]. This programme achieved a mean weight loss in 
the follow-up period (approximately 9 to 12  months 
post-programme) of 8.21  kg (SD = 2.72). Conversely, in 
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community pharmacy programmes conducted in the UK, 
the mean weight loss in pharmacy participants at session 
15 (approximately 9  months) was 2  kg [42] and 1.7  kg 
(1  year) [47], respectively. A study conducted by Har-
mon et  al. [48] in Maricopa County in Phoenix, which 
enrolled 12 individuals, 11 (92%) of whom completed 
the programme, achieved a mean weight loss of 5  kg 
(P-value < 0.001), with 45% of individuals losing 5% or 
more of their weight. Similar to our study, there was also a 
statistically significant reduction in participants’ BMI and 
WC [48]. So it was clear that this pharmacy-led weight 
management programme achieved higher weight loss 
results compared to other ones. In terms of the second-
ary outcomes (BMI, BP, WC, AUDIT-C score, Mediterra-
nean diet score), the programme was also successful. It is 
worth mentioning that the 10-week programme was suc-
cessful not only in terms of weight loss, but also the BMI 
classification was improved (P-value < 0.001). Interest-
ingly, during the follow-up period, further weight reduc-
tion was observed; but participants did not change their 
BMI category. Each BMI category reflects 14 kg in weight 
which is beyond 5–10% target weight loss. Therefore, a 
weight loss outcome is more achievable than a change 
in BMI category and should be maintained as the pri-
mary outcome of future services. Moreover, only 3 par-
ticipants were classified as hypertensive at the end of the 
programme compared to 19 originally (P-value < 0.001). 
This is another achievement of this WM programme 
and it accords with various studies [1, 49, 50], which 
mentioned that weight loss positively contributes to BP 
reduction leading to a reduction in CVD risk. Interest-
ingly, the study conducted by Boardman et al. [37] which 
evaluated a 6  month weight management programme 
stated that there was no alteration in participants’ BP fol-
lowing a 3  month period but there was after 6  months. 
This could be attributed to the more than double weight 
loss achieved (7.73 kg) compared to 3.07 kg observed by 
Boardman et al [37]. Another factor that may have helped 
the BP reduction during the programme was the increase 
in participants’ levels of activity. Chobanian et  al. [51] 
stated that regular physical activity reduces systolic and 
diastolic BP. It was obvious that during the weight man-
agement programme, participants significantly improved 
their exercise levels (P-value < 0.001) and decreased their 
sedentary lifestyle. The increase in physical activity can 
help in reducing weight and it can also lead to the pre-
vention of type 2 diabetes and CVD [52]. As stated in the 
Haskell et al. [53] study increased levels of physical activ-
ity should be an integral part of any weight loss option 
for obese individuals regardless of weight loss goals as it 
is associated with many CVD benefits [52]. In the study, 
83.8% of the participants who reported that they were 
drinking significantly decreased their AUDIT-C score 
after the programme’s conclusion (P-value < 0.001). Fur-
thermore, through the programme, there was a statisti-
cally significant decrease in both male (P-value = 0.004) 
and female (P-value < 0.001) participants WHtR, which 
is an early indicator of CVD risk [9]. There was also an 
increase in participants’ Mediterranean diet score [(≥ 10) 
(n = 10, 8.5% at initial screening and n = 33, 28.2% at the 
last visit)].
A minority of participants (n = 3) did not lose weight. 
They were offered the programme by three different 
pharmacists working in different pharmacies who ran 
the programme successfully with their other participants. 
For example, one pharmacist had 11 participants, and of 
those only 1 did not lose weight. Therefore, the lack of 
change in weight could have been a result of participants’ 
lack of effort, and their lack of commitment in prop-
erly following the advice and support gained from the 
programme.
The programme was successful, as 114 out of 117 
enrolled individuals reached the primary outcome of the 
programme, which was to achieve a weight reduction of 
at least 5% of their initial weight. A possible explanation 
for this success could be the fact that Greek pharmacists 
chose the WM programme as the first service to deliver 
by themselves. This means that pharmacists engaged 
more in delivering the programme, as it was chosen by 
them as a future need for enhancement of their current 
role. Another explanation for the programme’s success 
could be the continuous support that pharmacists had 
during the programme’s delivery from the lead pharma-
cist. An additional reason for the programme’s success 
could be the homogenous population both in terms of 
ethnic groups and also the fact that individuals with spe-
cial dietary requirements were excluded; the advice given 
was applicable to everyone, whereas in other countries 
such as the UK, advice needs to be tailored, as there are 
various cultures and different ethnic groups. A further 
possible reason for the programme’s success is the fact 
that structured training was offered using role playing, 
based on participants’ training needs and preferences. 
The Kocla-Kimble et  al. [54] study, which designed an 
active learning model for pharmacists offering diabetes 
care, showed an increase in their problem-solving abili-
ties, their communication skills and their self-confidence.
Another interesting observation which make this pro-
gramme successful was that none of the enrolled par-
ticipants dropped out of the programme, an achievement 
that contrasts with other WM programmes. For exam-
ple, in a study conducted by Nanchahal et al. [55], loss to 
follow-up was high (43%), similar to that of other weight 
loss studies in the UK [56, 57]. This could be explained as 
the length of the programme was concise and the meet-
ings took place biweekly rather than weekly. Another 
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factor that may have played a role was the training that 
pharmacists received on how to motivate people to make 
a change. This finding agrees with McCormick et al. [58], 
who indicated that training can have a “protective” role 
by minimising participants’ withdrawal from services.
According to the Bush et  al. [43] study, a factor that 
may have affected the relative success of this programme 
was the measured weight and WC of participants upon 
their entry onto the programme. It has been identified 
that people who are classified with high BMIs (≥ 35 kg/
m2) are more prone to lose more weight and conse-
quently to decrease their BMI categories, compared to 
those weighing less at the initial screening. In this study 
20 participants (17.1%) entered the programme with a 
BMI ≥ 35  kg/m2 with 52.1% of the whole sample being 
classified as obese at start of programme. This could 
be a reason why this weight management programme 
achieved higher weight loss results compared to the 
pharmacy-led weight management programmes offered 
elsewhere.
With regards to equipment, measuring tapes were pro-
vided to pharmacists. Other than that, each pharmacy 
had its own set of weighing scales (either electronic or 
analog) and BP machine (either electronic or manual). 
This might have acted as a limitation in the accuracy of 
readings, as not every pharmacy had the same equipment 
to use in the service. More specifically, measurements 
obtained might vary between the analog weight scale/
manual BP monitor and the electronic ones. Additionally, 
some participants thought that the area where the meet-
ings took place was not appropriate. A possible solution 
for this could be the introduction of consultation rooms 
to pharmacies in Greece, in order to increase privacy 
and confidentiality when offering public health services, 
a model that the UK already follows [59]. Although this 
is a possible solution to overcome this issue, the Wei-
dmann et al. [60] study showed that 47.3% of their sample 
stated lack of privacy as a barrier in Scottish pharmacies 
(a country where there are consultation rooms within 
pharmacies).
In terms of participants’ recruitment, there were vari-
ations between pharmacies. This may reflect the confi-
dence in approaching clients, the communication skills 
and the ability of pharmacists to motivate clients all of 
which are difficulties already highlighted by pharmacists 
[23]. Therefore, continuous training should be offered 
to ensure that pharmacists are always in a position to 
recruit and offer public health interventions.
In terms of limitations, it must be noted that the partic-
ipants’ collected data were recorded by pharmacists, and 
the analysis therefore depended on the accuracy of the 
recorded data, in particular on the measurements or cal-
culations obtained (in the case of using the paper-based 
booklets). In addition, the self-reported physical activity 
level by participants could be another limitation, as the 
duration might have possibly been overestimated. Par-
ticipants also self-reported their height, so there may be a 
difference between BMI measurements due to inaccura-
cies in the reported heights.
Although the sample size was achieved, it can be 
argued that it is small for the generalisation of findings 
across Greece. Therefore, the study needs to be repeated 
in another city in Greece to ensure its repeatability 
including broader inclusion criteria such as individuals 
with special dietary requirements such as vegetarians. 
Additionally, to implement the WM programme in other 
areas of Greece, the local pharmaceutical associations 
should agree their participation and a holistic training 
should be offered to pharmacists practising in different 
cities in Greece. Moreover, replication of the programme 
is very important as the success of the programme should 
be replicated in both larger and smaller cities rather than 
Patras to be able to generalise the results. Furthermore, 
a comparison of the demographics of the participants 
against the general population who are overweight/obese 
in Greece could not be performed due to the lack of the 
availability of this data. Therefore, it is difficult to con-
clude if the sample is representative of the population 
under investigation. Lastly, only about 12% of the phar-
macists in Patras agreed to take part. This was mainly 
due to lack of awareness and time challenges. Such limi-
tations need to be considered if this programme is to act 
as a model for pharmacy public health services.
Conclusions
Despite the limitations, our findings provide a model 
for a pharmacy-led public health programme revolving 
around weight management that can be used as a model 
for services in the future. The programme consisted of 
a 10-week intervention which assessed in addition to 
the weight loss, the BMI, WC, BP, AUDIT-C score and 
Mediterranean diet score. Thus, it had a more holistic 
approach. The programme benefited from structured vis-
its and supplementary materials to aid participants and 
pharmacists alike. All pharmacists were provided with 
training and the programme was evaluated both qualita-
tively and quantitatively. The programme had a success 
rate which supersedes any pharmacy-led programme for 
weight loss, thus adding to the evidence of pharmacists’ 
role in public health in general and to the potential role 
of Greek pharmacists in that regard in particular. Finally, 
pharmacy-led preventive services advance pharmacists’ 
clinical role in the community. The success of the phar-
macy-led interventions in a national level will add value 
to pharmacists’ role in addressing obesity as well as it will 
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give them financial incentives for offering such services 
into their daily practice.
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